司帕沙星对革兰氏阴性菌和革兰氏阳性菌的作用机制及耐药机制。
Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.
作者信息
Piddock L J, Zhu M
机构信息
Antimicrobial Agents Research Group, Medical School, University of Birmingham, United Kingdom.
出版信息
Antimicrob Agents Chemother. 1991 Nov;35(11):2423-7. doi: 10.1128/AAC.35.11.2423.
Abstract
The inhibition of DNA synthesis by sparfloxacin; accumulation of sparfloxacin into members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and staphylococci; induction of recA in Escherichia coli; and the optimum bactericidal concentration (OBC) were measured, and killing kinetics at the OBC were estimated. The OBC and maximum recA-inducing concentration in E. coli were both 1 microgram of sparfloxacin per ml. Accumulation was rapid; two- to threefold more sparfloxacin than ciprofloxacin accumulated in staphylococci and more sparfloxacin accumulated in staphylococci than in gram-negative bacteria. Laboratory mutants with decreased susceptibilities to quinolones alone or multiply resistant were selected from the Enterobacteriaceae and Staphylococcus aureus by using sparfloxacin.
摘要
测定了司帕沙星对DNA合成的抑制作用；司帕沙星在肠杆菌科细菌、铜绿假单胞菌和葡萄球菌中的蓄积情况；大肠杆菌中recA的诱导情况以及最佳杀菌浓度（OBC），并估计了在OBC时的杀菌动力学。大肠杆菌中的OBC和recA诱导的最大浓度均为每毫升1微克司帕沙星。蓄积迅速；葡萄球菌中司帕沙星的蓄积量比环丙沙星多两到三倍，且葡萄球菌中司帕沙星的蓄积量比革兰氏阴性菌多。通过使用司帕沙星，从肠杆菌科细菌和金黄色葡萄球菌中筛选出了对喹诺酮类药物敏感性降低或多重耐药的实验室突变株。
相似文献
1
Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.
Antimicrob Agents Chemother. 1991 Nov;35(11):2423-7. doi: 10.1128/AAC.35.11.2423.
2
Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
J Antimicrob Chemother. 1993 Jun;31(6):855-63. doi: 10.1093/jac/31.6.855.
3
Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.
Antimicrob Agents Chemother. 1994 Mar;38(3):422-7. doi: 10.1128/AAC.38.3.422.
4
Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
J Chemother. 1992 Feb;4(1):12-5. doi: 10.1080/1120009x.1992.11739131.
5
In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Chemotherapy. 1992;38(2):99-106. doi: 10.1159/000238948.
6
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k.
7
In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.
Chemotherapy. 1991;37(4):275-82. doi: 10.1159/000238867.
8
In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
Chemotherapy. 1996 Nov-Dec;42(6):410-25. doi: 10.1159/000239474.
9
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
J Chemother. 1997 Feb;9(1):9-16. doi: 10.1179/joc.1997.9.1.9.
10
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955.
引用本文的文献
1
Photosensitizer-specific bacterial stress responses in Escherichia coli reveal distinct targets in photoinduced inactivation.
Commun Biol. 2025 Oct 1;8(1):1413. doi: 10.1038/s42003-025-08881-4.
2
A Robust One-Step Recombineering System for Enterohemorrhagic .
Microorganisms. 2022 Aug 23;10(9):1689. doi: 10.3390/microorganisms10091689.
3
A Novel Device-Integrated Drug Delivery System for Local Inhibition of Urinary Tract Infection.
Front Microbiol. 2021 Jun 25;12:685698. doi: 10.3389/fmicb.2021.685698. eCollection 2021.
4
Unique features of apicoplast DNA gyrases from Toxoplasma gondii and Plasmodium falciparum.
BMC Bioinformatics. 2014 Dec 19;15(1):416. doi: 10.1186/s12859-014-0416-9.
5
Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.
Antimicrob Agents Chemother. 2002 Jul;46(7):2276-8. doi: 10.1128/AAC.46.7.2276-2278.2002.
6
Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2002 Mar;46(3):813-20. doi: 10.1128/AAC.46.3.813-820.2002.
7
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
Antimicrob Agents Chemother. 2000 Mar;44(3):798-801. doi: 10.1128/AAC.44.3.798-801.2000.
8
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
Drugs. 1997 Apr;53(4):700-25. doi: 10.2165/00003495-199753040-00010.
9
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Antimicrob Agents Chemother. 1996 Aug;40(8):1768-74. doi: 10.1128/AAC.40.8.1768.
10
Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients.
Antimicrob Agents Chemother. 1993 Apr;37(4):662-6. doi: 10.1128/AAC.37.4.662.
本文引用的文献
1
Genetic control of DNA initiation in Escherichia coli.
J Mol Biol. 1973 Feb 25;74(2):205-21. doi: 10.1016/0022-2836(73)90107-1.
2
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.
Antimicrob Agents Chemother. 1986 Aug;30(2):248-53. doi: 10.1128/AAC.30.2.248.
3
Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12.
Antimicrob Agents Chemother. 1988 Aug;32(8):1113-8. doi: 10.1128/AAC.32.8.1113.
4
Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 1986 Jan;29(1):1-6. doi: 10.1128/AAC.29.1.1.
5
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.
Antimicrob Agents Chemother. 1986 Apr;29(4):639-44. doi: 10.1128/AAC.29.4.639.
6
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
Antimicrob Agents Chemother. 1989 Aug;33(8):1318-25. doi: 10.1128/AAC.33.8.1318.
7
Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.
Antimicrob Agents Chemother. 1989 Mar;33(3):283-90. doi: 10.1128/AAC.33.3.283.
8
Fluorometric assay for fleroxacin uptake by bacterial cells.
Antimicrob Agents Chemother. 1989 Jan;33(1):27-9. doi: 10.1128/AAC.33.1.27.
9
Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.
Antimicrob Agents Chemother. 1990 Sep;34(9):1843-5. doi: 10.1128/AAC.34.9.1843.
10
Mechanism of action of lomefloxacin.
Antimicrob Agents Chemother. 1990 Jun;34(6):1088-93. doi: 10.1128/AAC.34.6.1088.
Zotero 插件